InnoCan Pharma (INNO) Q3 2024 earnings summary

Executive summary

• Nine-month revenue reached $24.0 million, up 174% year-over-year, with third quarter revenue at $8.6 million, up 111% year-over-year.

• Gross profit for the nine-month period increased 183% to $21.8 million; third quarter gross profit rose 112% to $7.8 million.

• Operating profit for the third quarter was $0.4 million, reversing a $1.2 million loss from the prior year.

• Net profit for the third quarter was $0.3 million, compared to a net loss of $1.8 million in the same quarter last year.

• Nine consecutive quarters of revenue growth, driven by new product introductions and increased brand awareness.

Financial highlights

• Revenue for the nine-month period up 174% year-over-year to $24.0 million.

• Gross profit for the nine-month period up 183% to $21.8 million.

• Third quarter operating profit of $0.4 million, up $1.6 million from a loss last year.

• Third quarter net profit of $0.3 million, up $2.1 million from a net loss last year.

Outlook and guidance

• Management highlights ongoing commitment to pharmaceutical innovation, especially in non-opioid chronic pain management.

• Continued focus on expanding product offerings and increasing brand awareness.